Influence of cardiovas- cular absolute risk assessment on prescribing of antihypertensive and lipid-lowering medications: a cluster randomized controlled trial. Am Heart J. 2014;167:28 35. S8.1.2-41. Rafter N, Connor J, Hall J, et al. Cardiovascular medications in primary care: treatment gaps and targeting by absolute risk. N Z Med J. 2005;118:U1676. S8.1.2-42. Yong TY, Phillipov G, Phillips PJ. Management outcomes of patients with type 2 diabetes: targeting the 10-year absolute risk of coronary heart disease. Med J Aust. 2007;186:622 4. S8.1.2-43. Webster RJ, Heeley EL, Peiris DP, et al. Gaps in cardiovascular dis- ease risk management in Australian general practice. Med J Aust. 2009;191:324 9. S8.1.2-44. Frikke-Schmidt R, Tybj rg-Hansen A, Schnohr P, et al. Common clinical practice versus new PRIM score in predicting coronary heart disease risk. Atherosclerosis. 2010;213:532 8. S8.1.2-45. Heeley EL, Peiris DP, Patel AA, et al. Cardiovascular risk percep- tion and evidence practice gaps in Australian general practice (the AusHEART study). Med J Aust. 2010;192:254 9. S8.1.2-46. Shillinglaw B, Viera AJ, Edwards T, et al. Use of global coronary heart disease risk assessment in practice: a cross-sectional survey of a sample of U.S. physicians. BMC Health Serv Res. 2012;12:20. S8.1.2-47. Game FL, Bartlett WA, Bayly GR, et al. Comparative accuracy of cardiovascular risk prediction methods in patients with diabetes mellitus. Diabetes Obes Metab. 2001;3:279 86. S8.1.2-48. Bastuji-Garin S, Deverly A, Moyse D, et al. The Framingham pre- diction rule is not valid in a European population of treated hyper- tensive patients. J Hypertens. 2002;20:1973 80. S8.1.2-49. Menotti A, Puddu PE, Lanti M. The estimate of cardiovascular risk. Theory, tools and problems. Ann Ital Med Int. 2002;17:81 94. S8.1.2-50. de Visser CL, Bilo HJG, Thomsen TF, et al. Prediction of coronary heart disease: a comparison between the Copenhagen risk score and the Framingham risk score applied to a Dutch population. J Intern Med. 2003;253:553 62. S8.1.2-51. Persson M, Carlberg B, Weinehall L, et al. Risk stratification by guidelines compared with risk assessment by risk equations applied to a MONICA sample. J Hypertens. 2003;21:1089 95. S8.1.2-52. Doust J, Sanders S, Shaw J, et al. Prioritising CVD prevention therapy absolute risk versus individual risk factors. Aust Fam Physician. 2012;41:805 9. S8.1.2-53. Allan GM, Nouri F, Korownyk C, et al. Agreement among cardio- vascular disease risk calculators. Circulation. 2013;127:1948 56. S8.1.2-54. Diverse Populations Collaborative Group. Prediction of mortality from coronary heart disease among diverse populations: is there a common predictive function? Heart. 2002;88:222 8. S8.1.2-55. van den Hoogen PC, Feskens EJ, Nagelkerke NJ, et al. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med. 2000;342:1 8. S8.1.2-56. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S49 73. S8.1.2-57. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce athero- sclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S1 45. S8.1.2-58. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pres- sure lowering on outcome incidence in hypertension: 3. Effects in patients at different levels of cardiovascular risk overview and meta-analyses of randomized trials. J Hypertens. 2014;32:2305 14. S8.1.2-59. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating pre- hypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354:1685 97. S8.1.2-60. Julius S, Kaciroti N, Egan BM, et al. TROPHY study: outcomes based on the Seventh Report of the Joint National Committee on Hypertension definition of hypertension. J Am Soc Hypertens. 2008;2:39 43. S8.1.2-61. Luders S, Schrader J, Berger J, et al. The PHARAO study: pre- vention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens. 2008;26:1487 96. S8.1.2-62. Fuchs SC, Poli-de-Figueiredo CE, Figueiredo Neto JA, et al. Effectiveness of chlorthalidone plus amiloride for the prevention of hypertension: the PREVER Prevention Randomized Clinical Trial. J Am Heart Assoc. 2016;5:e004248. S8.1.2-63. Lonn EM, Bosch J, Lopez-Jaramillo P, et al. Blood-pressure lower- ing in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2009 20. 8.1.3. Follow-Up After Initial BP Evaluation S8.1.3-1. Ambrosius WT, Sink KM, Foy CG, et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials. 2014;11:532 46. S8.1.3-2. Cushman WC, Grimm RH Jr, Cutler JA, et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007;99:44i 55i. S8.1.3-3. CarsonAP, Howard G, Burke GL, et al. Ethnic differences in hyper- tension incidence among middle-aged and older adults: the Multi- Ethnic study of Atherosclerosis. Hypertension. 2011;57:1101 7. 8.1.4. General Principles of Drug Therapy S8.1.4-1. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. ONTARGET Investigators. N Engl J Med. 2008;358:1547 59. S8.1.4-2. Parving H-H, Brenner BM, McMurray JJV, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204 13. S8.1.4-3. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892 903. S8.1.4-4. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA. 1967;202:1028 34. S8.1.4-5. Five-year findings of the hypertension detection and follow-up pro- gram. I. Reduction in mortality of persons with high blood pres- sure, including mild hypertension. Hypertension Detection and Follow-upProgramCooperativeGroup.JAMA.1979;242:2562 71. S8.1.4-6. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265:3255 64. S8.1.4-7. Kostis JB, Cabrera J, Cheng JQ, et al. Association between chlorthalidone treatment of systolic hypertension and long-term survival. JAMA. 2011;306:2588 93. S8.1.4-8. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospec- tive epidemiological studies. BMJ. 2009;338:b1665. S8.1.4-9. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at differ- ent baseline and achieved blood pressure levels overview and meta- analyses of randomized trials. J Hypertens. 2014;32:2296 304. S8.1.4-10. Czernichow S, Zanchetti A, Turnbull F, et al. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens. 2011;29:4 16. S8.1.4-11. Fretheim A, Odgaard-Jensen J, Brors O, et al. Comparative effec- tiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis. BMC Med. 2012;10:33. S8.1.4-12. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393 404. S8.1.4-13. Gradman AH, Basile JN, Carter BL, et al. Combination therapy in hypertension. J Clin Hypertens (Greenwich). 2011;13:146 54. S8.1.4-14. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. ACCORD Study Group. N Engl J Med. 2010;362:1575 85. S8.1.4-15. Chobanian AV, Bakris GL, Black HR, et al; the National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206 52. 8.1.5. BP Goal for Patients With Hypertension S8.1.5-1. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels updated overview and meta-analyses of ran- domized trials. J Hypertens. 2016;34:613 22. S8.1.5-2. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435 43. S8.1.5-3. Verdecchia P, Angeli F, Gentile G, et al. More versus less intensive blood pressure-lowering strategy: cumulative evidence and trial sequential analysis. Hypertension. 2016;68:642 53. S8.1.5-4. Bangalore S, Toklu B, Gianos E, et al. Optimal systolic blood pres- sure target after SPRINT: insights from a network meta-analysis of randomized trials. Am J Med. 2017;30:707 19.e8. Whelton et al 2017 High Blood Pressure Clinical Practice Guideline e93 S8.1.5-5. Bundy JD, Li C, Stuchlik P, et al. Systolic blood pressure reduc- tion and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol. 2017;2:775 81. S8.1.5-6. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating pre- hypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354:1685 97. S8.1.5-7. Lawes CMM, Bennett DA, Lewington S, et al. Blood pressure and coronary heart disease: a review of the evidence. Semin Vasc Med. 2002;2:355 68. S8.1.5-8. Lonn EM, Bosch J, Lopez-Jaramillo P, et al. Blood-pressure lower- ing in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2009 20. S8.1.5-9. Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA. 1993;270:713 24. S8.1.5-10. Reboussin DM, Allen NB, Griswold ME, et al. Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e116 e135. S8.1.5-11. Brunstrom M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ. 2016;352:i717. S8.1.5-12. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957 67. S8.1.5-13. Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive blood pres- sure lowering on the progression of chronic kidney disease: a sys- tematic review and meta-analysis. CMAJ. 2013;185:949 57. S8.1.5-14. Cushman WC, Evans GW, Byington RP, et al. Effects of inten- sive blood-pressure control in type 2 diabetes mellitus. ACCORD Study. N Engl J Med. 2010;362:1575 85. S8.1.5-15. Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group. N Engl J Med. 2015;373:2103 16. S8.1.5-16. SPS3 Study Group. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;382:507 15. S8.1.5-17. PerkovicV, RodgersA. Redefining blood-pressure targets SPRINT starts the marathon. N Engl J Med. 2015;373:2175 8. S8.1.5-18. Lawes CMM, Rodgers A, Bennett DA, et al. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens. 2003;21:707 16. S8.1.5-19. Allen NB, Siddique J, Wilkins JT, et al. Blood pressure trajectories in early adulthood and subclinical atherosclerosis in middle age. JAMA. 2014;311:490 7. S8.1.5-20. Ference BA, Julius S, Mahajan N, et al. Clinical effect of naturally random allocation to lower systolic blood pressure beginning before the development of hypertension. Hypertension. 2014;63:1182 8. 8.1.6. Choice of Initial Medication S8.1.6-1. Reboussin DM, Allen NB, Griswold ME, et al. Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e116 e135. S8.1.6-2. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes asso- ciated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289:2534 44. S8.1.6-3. ALLHAT Officers and Coordinators for theALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or cal- cium channel blocker vs diuretic: the Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981 97. S8.1.6-4. Ferrucci L, Guralnik JM, Pahor M, et al. Hospital diagnoses, Medicare charges, and nursing home admissions in the year when older persons become severely disabled. JAMA. 1997;277:728 34. S8.1.6-5. Curtis LH, Whellan DJ, Hammill BG, et al. Incidence and preva- lence of heart failure in elderly persons, 1994 2003. Arch Intern Med. 2008;168:418 24. S8.1.6-6. Bleumink GS, Knetsch AM, Sturkenboom MCJM, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J. 2004;25:1614 9. S8.1.6-7. Bertoni AG, Hundley WG, Massing MW, et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care. 2004;27:699 703. S8.1.6-8. Ogedegbe G, Shah NR, Phillips C, et al. Comparative effective- ness of angiotensin-converting enzyme inhibitor-based treatment on cardiovascular outcomes in hypertensive blacks versus whites. J Am Coll Cardiol. 2015;66:1224 33. S8.1.6-9. Leenen FHH, Nwachuku CE, Black HR, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Hypertension. 2006;48:374 84. S8.1.6-10. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha- blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2003;42:239 46. S8.1.6-11. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospec- tive epidemiological studies. BMJ. 2009;338:b1665. S8.1.6-12. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure- lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs-over- view and meta-analyses. J Hypertens. 2015;33:1321 41. S8.1.6-13. ZhangY, Sun N, Jiang X, et al. Comparative efficacy of -blockers on mortality and cardiovascular outcomes in patients with hyper- tension: a systematic review and network meta-analysis. J Am Soc. Hypertens. 2017;11:394 401. S8.1.6-14. Larochelle P, Tobe SW, Lacourciere Y. -Blockers in hyperten- sion: studies and meta-analyses over the years. Can J Cardiol. 2014;30:S16 22. 8.1.6.1. Choice of Initial Monotherapy Versus Initial Combination Drug Therapy S8.1.6.1-1. Chobanian AV, Bakris GL, Black HR, et al; the National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206 52. S8.1.6.1-2. Law MR, Wald NJ, Morris JK, et al. Value of low dose combina- tion treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326:1427. S8.1.6.1-3. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose com- binations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713 9. S8.1.6.1-4. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417 28. S8.1.6.1-5. Sundstrom J, Arima H, Jackson R, et al. Effects of blood pressure reduction in mild hypertension: a systematic review and meta- analysis. Ann Intern Med. 2015;162:184 91. S8.1.6.1-6. Luders S, Schrader J, Berger J, et al. The PHARAO study: pre- vention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens. 2008;26:1487 96. S8.1.6.1-7. Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. A cooperative study. JAMA. 1977;237:255 61. 8.2. Achieving BP Control in Individual Patients S8.2-1. Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA. 1993;270:713 24. S8.2-2. Senn S. Individual response to treatment: is it a valid assumption? BMJ. 2004;329:966 8. 8.3. Follow-Up of BP During Antihypertensive Drug Therapy S8.3-1. Ambrosius WT, Sink KM, Foy CG, et al. The design and ratio- nale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials. 2014;11:532 46. S8.3-2. Cushman WC, Grimm RH Jr, Cutler JA, et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007;99:44i 55i. 8.3.1. Follow-Up After Initiating Antihypertensive Drug Therapy S8.3.1-1. Ambrosius WT, Sink KM, Foy CG, et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials. 2014;11:532 46. S8.3.1-2. Cushman WC, Grimm RH Jr, Cutler JA, et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007;99:44i 55i. S8.3.1-3. Xu W, Goldberg SI, Shubina M, et al. Optimal systolic blood pres- sure target, time to intensification, and time to follow-up in treat- ment of hypertension: population based retrospective cohort study. BMJ. 2015;350:h158. 8.3.2. Monitoring Strategies to Improve Control of BP in Patients on Drug Therapy for High BP S8.3.2-1. Brennan T, Spettell C, Villagra V, et al. Disease management to promote blood pressure control among African Americans. Popul Health Manag. 2010;13:65 72. S8.3.2-2. Bosworth HB, Olsen MK, Grubber JM, et al. Two self-management interventions to improve hypertension control: a randomized trial. Ann Intern Med. 2009;151:687 95. S8.3.2-3. Bosworth HB, Powers BJ, Olsen MK, et al. Home blood pres- sure management and improved blood pressure control: results from a randomized controlled trial. Arch Intern Med. 2011;171: 1173 80. S8.3.2-4. Green BB, Cook AJ, Ralston JD, et al. Effectiveness of home blood pressure monitoring, Web communication, and pharmacist care on hypertension control: a randomized controlled trial. JAMA. 2008;299:2857 67. S8.3.2-5. Heisler M, Hofer TP, Schmittdiel JA, et al. Improving blood pres- sure control through a clinical pharmacist outreach program in patients with diabetes mellitus in 2 high-performing health systems: the adherence and intensification of medications cluster random- ized, controlled pragmatic trial. Circulation. 2012;125:2863 72. S8.3.2-6. Margolis KL,Asche SE, BergdallAR, et al. Effect of home blood pres- sure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial. JAMA. 2013;310:46 56. 9. Hypertension in Patients With Comorbidities S9-1. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. Circulation. 2011;123:2434 506. S9-2. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guide- line for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128: e240 327. S9-3. Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/ AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2014;130:1749 67. S9-4. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ ACC guideline on the management of patients with lower extrem- ity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e726 79. 9.1. Stable Ischemic Heart Disease S9.1-1. Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group. N Engl J Med. 2015;373:2103 16. S9.1-2. Bundy JD, Li C, Stuchlik P, et al. Systolic blood pressure reduc- tion and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol. 2017;2:775 81. S9.1-3. Leenen FHH, Nwachuku CE, Black HR, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2006;48:374 84. S9.1-4. Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens. 2006;24:2163 8. S9.1-5. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha- blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2003;42:239 46. S9.1-6. Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/ AATS/PCNA/SCAI/STS focused update of the Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2014;130:1749 67. S9.1-7. Fox KM. EURopean trial On reduction of cardiac events with Perindopril in stable coronaryArtery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782 8. S9.1-8. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospec- tive epidemiological studies. BMJ. 2009;338:b1665. S9.1-9. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunc- tion after myocardial infarction. Results of the survival and ven- tricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669 77. S9.1-10. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-con- verting-enzyme inhibitor, ramipril, on cardiovascular events in high- risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145 53. S9.1-11. Leon MB, Rosing DR, Bonow RO, et al. Clinical efficacy of vera- pamil alone and combined with propranolol in treating patients with chronic stable angina pectoris. Am J Cardiol. 1981;48:131 9. S9.1-12. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350:757 64. S9.1-13. Freemantle N, Cleland J, Young P, et al. Beta Blockade after myo- cardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730 7. S9.1-14. de Peuter OR, Lussana F, Peters RJG, et al. A systematic review of selective and non-selective beta blockers for prevention of vascular events in patients with acute coronary syndrome or heart failure. Neth J Med. 2009;67:284 94. S9.1-15. Bavry AA, Anderson RD, GongY, et al. Outcomes among hyperten- sive patients with concomitant peripheral and coronary artery dis- ease: findings from the INternational VErapamil-SR/Trandolapril STudy. Hypertension. 2010;55:48 53. S9.1-16. Piller LB, Simpson LM, Baraniuk S, et al. Characteristics and long- term follow-up of participants with peripheral arterial disease dur- ing ALLHAT. J Gen Intern Med. 2014;29:1475 83. S9.1-17. Rosendorff C, Lackland DT, Allison M, et al. Treatment of hyper- tension in patients with coronary artery disease: a scientific state- ment from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Circulation. 2015;131:e435 70. Whelton et al 2017 High Blood Pressure Clinical Practice Guideline e95 S9.1-18. Ekelund LG, Olsson AG, Oro L, et al. Effects of the cardiose- lective beta-adrenergic receptor blocking agent metoprolol in angina pectoris. Subacute study with exercise tests. Br Heart J. 1976;38:155 61. S9.1-19. Aronow WS, Turbow M, Van Camp S, et al. The effect of timolol vs placebo on angina pectoris. Circulation. 1980;61:66 9. S9.1-20. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. Circulation. 2011;123:2434 506. S9.1-21. Aronow WS, Frishman WH. Angina pectoris in the elderly. Aronow WS, Fleg JL, Rich MW. Tresch and Aronow's Cardiovascular Disease in the Elderly. 2013; CRC Press, Taylor & Francis Group: Boca Raton, FL:215 37. S9.1-22. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF second- ary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124:2458 73. S9.1-23. Carlberg B, Samuelsson O, Lindholm LH.Atenolol in hypertension: is it a wise choice? Lancet. 2004;364:1684 9. S9.1-24. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guide- lines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159 219. S9.1-25. Fihn SD, Gardin JM,Abrams J, et al. 2012ACCF/AHA/ACP/AATS/ PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126:e354 471. 9.2. Heart Failure S9.2-1. Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive blood pres- sure lowering on the progression of chronic kidney disease: a sys- tematic review and meta-analysis. CMAJ. 2013;185:949 57. S9.2-2. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels updated overview and meta-analyses of ran- domized trials. J Hypertens. 2016;34:613 22. S9.2-3. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435 43. S9.2-4. Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016;134:e282 93. S9.2-5. Visser M, Langlois J, Guralnik JM, et al. High body fatness, but not low fat-free mass, predicts disability in older men and women: the Cardiovascular Health Study. Am J Clin Nutr. 1998;68:584 90. S9.2-6. Goodpaster BH, Park SW, Harris TB, et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci. 2006;61:1059 64. S9.2-7. Butler J, Kalogeropoulos AP, Georgiopoulou VV, et al. Systolic blood pressure and incident heart failure in the elderly. The Cardiovascular Health Study and the Health, Ageing and Body Composition Study. Heart. 2011;97:1304 11. S9.2-8. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of theAmerican College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240 327. S9.2-9. Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group. N Engl J Med. 2015;373:2103 16. S9.2-10. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957 67. 9.2.1. Heart Failure With Reduced Ejection Fraction S9.2.1-1. Goldstein RE, Boccuzzi SJ, Cruess D, et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation. 1991;83:52 60. S9.2.1-2. Aronow WS, Ahn C, Kronzon I. Normal left ventricular ejection fraction in older persons with congestive heart failure. Chest. 1998;113:867 9. S9.2.1-3. Aronow WS, Ahn C, Kronzon I. Comparison of incidences of con- gestive heart failure in older African-Americans, Hispanics, and whites. Am J Cardiol. 1999;84:611 2; A9. S9.2.1-4. Gottdiener JS, McClelland RL, Marshall R, et al. Outcome of con- gestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med. 2002;137:631 9. S9.2.1-5. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251 9. S9.2.1-6. Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart fail- ure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999;33:1948 55. S9.2.1-7. Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016;134:e282 93. S9.2.1-8. Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet. 1985;1:1349 54. S9.2.1-9. Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA. 1997;278:212 6. S9.2.1-10. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hyper- tension in patients 80 years of age or older. N Engl J Med. 2008;358:1887 98. S9.2.1-11. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospec- tive epidemiological studies. BMJ. 2009;338:b1665. S9.2.1-12. Davis BR, Kostis JB, Simpson LM, et al. Heart failure with pre- served and reduced left ventricular ejection fraction in the antihy- pertensive and lipid-lowering treatment to prevent heart attack trial. Circulation. 2008;118:2259 67. S9.2.1-13. Piller LB, Baraniuk S, Simpson LM, et al. Long-term follow-up of participants with heart failure in the Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Circulation. 2011;124:1811 8. S9.2.1-14. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137 61. 9.2.2. Heart Failure With Preserved Ejection Fraction S9.2.2-1. Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131:34 42. S9.2.2-2. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline forthemanagementofheartfailure:areportoftheAmericanCollege of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240 327. S9.2.2-3. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. Am J Cardiol. 1997;80:207 9. S9.2.2-4. vanVeldhuisen DJ, Cohen-SolalA, Bohm M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol. 2009;53:2150 8. S9.2.2-5. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejec- tion fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777 81. S9.2.2-6. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456 67. S9.2.2-7. Aronow WS, Ahn C, Kronzon I. Normal left ventricular ejection fraction in older persons with congestive heart failure. Chest. 1998;113:867 9. S9.2.2-8. Aronow WS, Ahn C, Kronzon I. Comparison of incidences of con- gestive heart failure in older African-Americans, Hispanics, and whites. Am J Cardiol. 1999;84:611 2; A9. S9.2.2-9. Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart fail- ure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999;33:1948 55. S9.2.2-10. Gottdiener JS, McClelland RL, Marshall R, et al. Outcome of con- gestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med. 2002;137:631 9. S9.2.2-11. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251 9. S9.2.2-12. Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute. Circulation. 2009;119:3070 7. S9.2.2-13. Bhuiyan T, Maurer MS. Heart failure with preserved ejection frac- tion: persistent diagnosis, therapeutic enigma. Curr Cardiovasc Risk Rep. 2011;5:440 9. S9.2.2-14. Kato S, Onishi K, Yamanaka T, et al. Exaggerated hyperten- sive response to exercise in patients with diastolic heart failure. Hypertens Res. 2008;31:679 84. S9.2.2-15. St Gyalai-Korpos I, Tomescu M, Pogorevici A. Hypertensive acute pulmonary oedema as expression of diastolic heart failure. Rom J Intern Med. 2008;46:153 7. S9.2.2-16. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. Circulation. 2011;123:2434 506. S9.2.2-17. Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA. 1997;278:212 6. S9.2.2-18. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hyper- tension in patients 80 years of age or older. N Engl J Med. 2008;358:1887 98. S9.2.2-19. Piller LB, Baraniuk S, Simpson LM, et al. Long-term follow-up of participants with heart failure in the antihypertensive and lipid-low- ering treatment to prevent heart attack trial (ALLHAT). Circulation. 2011;124:1811 8. S9.2.2-20. Davis BR, Kostis JB, Simpson LM, et al. Heart failure with pre- served and reduced left ventricular ejection fraction in the antihy- pertensive and lipid-lowering treatment to prevent heart attack trial. Circulation. 2008;118:2259 67. S9.2.2-21. Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodies- terase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309:1268 77. 9.3. Chronic Kidney Disease S9.3-1. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994;330:877 84. S9.3-2. Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal dis- ease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365:939 46. S9.3-3. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pres- sure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421 31. S9.3-4. Upadhyay A, Earley A, Haynes SM, et al. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med. 2011;154:541 8. S9.3-5. Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive blood pres- sure lowering on the progression of chronic kidney disease: a sys- tematic review and meta-analysis. CMAJ. 2013;185:949 57. S9.3-6. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kid- ney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta- analysis. Ann Intern Med. 2003;139:244 52. S9.3-7. Lambers Heerspink HJ, Brantsma AH, de Zeeuw D, et al. Albuminuria assessed from first-morning-void urine samples ver- sus 24-hour urine collections as a predictor of cardiovascular mor- bidity and mortality. Am J Epidemiol. 2008;168:897 905. S9.3-8. Lambers Heerspink HJ, Gansevoort RT, Brenner BM, et al. Comparison of different measures of urinary protein excretion for prediction of renal events. J Am Soc Nephrol. 2010;21:1355 60. S9.3-9. Contreras G, Greene T, Agodoa LY, et al. Blood pressure con- trol, drug therapy, and kidney disease. Hypertension. 2005;46: 44 50. S9.3-10. Esnault VLM, Brown EA, Apetrei E, et al. The effects of amlodip- ine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, dou- ble-blind, placebo-controlled study. Clin Ther. 2008;30:482 98. S9.3-11. Marin R, Ruilope LM, Aljama P, et al. A random comparison of fosinopril and nifedipine GITS in patients with primary renal dis- ease. J Hypertens. 2001;19:1871 6. S9.3-12. Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting- Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med. 1997;127:337 45. S9.3-13. Reboussin DM, Allen NB, Griswold ME, et al. Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ ASPC/NMA/PCNA guideline for the prevention, detection, evalu- ation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e116 e135. S9.3-14. Muntner P, Anderson A, Charleston J, et al. Hypertension aware- ness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2010;55:441 51. S9.3-15. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guide- line for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507 20. S9.3-16. National Clinical Guideline Centre (UK). Chronic Kidney Disease (Partial Update): Early Identification and Management of Chronic Kidney Disease in Adults in Primary and Secondary Care. London, UK: National Institute for Health and Care Excellence (UK); 2014. S9.3-17. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guide- lines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159 219. S9.3-18. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl (2011). 2012;2(5):337 414. S9.3-19. Kanno A, Metoki H, Kikuya M, et al. Usefulness of assessing masked and white-coat hypertension by ambulatory blood pressure Whelton et al 2017 High Blood Pressure Clinical Practice Guideline e97 monitoring for determining prevalent risk of chronic kidney dis- ease: the Ohasama study. Hypertens Res. 2010;33:1192 8. S9.3-20. Terawaki H, Metoki H, Nakayama M, et al. Masked hypertension determined by self-measured blood pressure at home and chronic kidney disease in the Japanese general population: the Ohasama study. Hypertens Res. 2008;31:2129 35. S9.3-21. Minutolo R, Gabbai FB, Agarwal R, et al. Assessment of achieved clinic and ambulatory blood pressure recordings and outcomes during treatment in hypertensive patients with CKD: a multicenter prospective cohort study. Am J Kidney Dis. 2014;64:744 52. S9.3-22. Drawz PE, Alper AB, Anderson AH, et al. Masked hypertension and elevated nighttime blood pressure in CKD: prevalence and association with target organ damage. Clin J Am Soc Nephrol. 2016;11:642 52. S9.3-23. Agarwal R, Andersen MJ. Prognostic importance of ambulatory blood pressure recordings in patients with chronic kidney disease. Kidney Int. 2006;69:1175 80. S9.3-24. Navaneethan SD, Schold JD, Arrigain S, et al. Cause-specific deaths in non-dialysis-dependent CKD. J Am Soc Nephrol. 2015;26:2512 20. S9.3-25. Matsushita K, van der Velde M, Astor BC, et al. Association of esti- mated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collabora- tive meta-analysis. Chronic Kidney Disease Prognosis Consortium. Lancet. 2010;375:2073 81. S9.3-26. Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group. N Engl J Med. 2015;373:2103 16. S9.3-27. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. ACCORD Study Group. N Engl J Med. 2010;362:1575 85. S9.3-28. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S49 73. S9.3-29. Kovesdy CP, Alrifai A, Gosmanova EO, et al. Age and outcomes associated with BP in patients with incident CKD. Clin J Am Soc Nephrol. 2016;11:821 31. S9.3-30. Weiss JW, Peters D, Yang X, et al. Systolic BP and mortality in older adults with CKD. Clin J Am Soc Nephrol. 2015;10: 1553 9. S9.3-31. Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs standard blood pressure control and cardiovascular disease out- comes in adults aged 75 years: a randomized clinical trial. JAMA. 2016;315:2673 82. S9.3-32. Holtkamp FA, de Zeeuw D, Thomas MC, et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int. 2011;80:282 7. S9.3-33. Hricik DE, Browning PJ, Kopelman R, et al. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney. N Engl J Med. 1983;308:373 6. S9.3-34. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, cap- topril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893 906. S9.3-35. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. ONTARGET Investigators. N Engl J Med. 2008;358:1547 59. S9.3-36. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892 903. S9.3-37. Parving H-H, Brenner BM, McMurray JJV, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204 13. S9.3-38. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study.Ann Intern Med. 1995;123:754 62. S9.3-39. Appel LJ, Wright JT Jr, Greene T, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010;363:918 29. S9.3-40. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957 67. S9.3-41. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels updated overview and meta-analyses of ran- domized trials. J Hypertens. 2016;34:613 22. S9.3-42. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435 43. S9.3-43. Ninomiya T, Perkovic V, Turnbull F, et al. Blood pressure lower- ing and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled tri- als. BMJ. 2013;347:f5680. 9.3.1. Hypertension After Renal Transplantation S9.3.1-1. Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group. N Engl J Med. 2015;373:2103 16. S9.3.1-2. Cross NB, Webster AC, Masson P, et al. Antihypertensive treat- ment for kidney transplant recipients. Cochrane Database Syst Rev. 2009:CD003598. S9.3.1-3. Cosio FG, Pelletier RP, Pesavento TE, et al. Elevated blood pres- sure predicts the risk of acute rejection in renal allograft recipients. Kidney Int. 2001;59:1158 64. S9.3.1-4. Peschke B, Scheuermann EH, Geiger H, et al. Hypertension is associated with hyperlipidemia, coronary heart disease and chronic graft failure in kidney transplant recipients. Clin Nephrol. 1999;51:290 5. S9.3.1-5. Mange KC, Cizman B, Joffe M, et al. Arterial hypertension and renal allograft survival. JAMA. 2000;283:633 8. S9.3.1-6. Mange KC, Feldman HI, Joffe MM, et al. Blood pressure and the survival of renal allografts from living donors. J Am Soc Nephrol. 2004;15:187 93. S9.3.1-7. Taler SJ, Textor SC, Canzanello VJ, et al. Cyclosporin-induced hypertension: incidence, pathogenesis and management. Drug Saf. 1999;20:437 49. S9.3.1-8. Taler SJ, Textor SC, Canzanello VJ, et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. Transplantation. 1996;62:1588 92. S9.3.1-9. Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose cortico- steroid therapy. Ann Surg. 2008;248:564 77. S9.3.1-10. Vincenti F, Schena FP, Paraskevas S, et al. A randomized, mul- ticenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant. 2008;8:307 16. S9.3.1-11. Rostaing L, Vincenti F, Grinyo J, et al. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant. 2013;13:2875 83. S9.3.1-12. Opelz G, Dohler B; Collaborative Transplant Study. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant. 2005;5:2725 31. S9.3.1-13. Hillebrand U, Suwelack BM, Loley K, et al. Blood pressure, anti- hypertensive treatment, and graft survival in kidney transplant patients. Transpl Int. 2009;22:1073 80. S9.3.1-14. Wadei HM, Amer H, Taler SJ, et al. Diurnal blood pressure changes one year after kidney transplantation: relationship to allograft function, histology, and resistive index. J Am Soc Nephrol. 2007;18:1607 15. S9.3.1-15. Ambrosi P, Kreitmann B, Habib G. Home blood pressure moni- toring in heart transplant recipients: comparison with ambulatory blood pressure monitoring. Transplantation. 2014;97:363 7. S9.3.1-16. Haydar AA, Covic A, Jayawardene S, et al. Insights from ambula- tory blood pressure monitoring: diagnosis of hypertension and diur- nal blood pressure in renal transplant recipients. Transplantation. 2004;77:849 53. S9.3.1-17. Jennings DL, Taber DJ. Use of renin-angiotensin-aldosterone sys- tem inhibitors within the first eight to twelve weeks after renal transplantation. Ann Pharmacother. 2008;42:116 20. 9.4. Cerebrovascular Disease S9.4-1. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics 2017 update: a report from the American Heart Association. Circulation. 2017;135:e146 603. S9.4-2. Boan AD, Lackland DT, Ovbiagele B. Lowering of blood pressure for recurrent stroke prevention. Stroke. 2014;45:2506 13. 9.4.1. Acute Intracerebral Hemorrhage S9.4.1-1. Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013;368:2355 65. S9.4.1-2. Qureshi AI, Palesch YY, Barsan WG, et al. Intensive blood-pres- sure lowering in patients with acute cerebral hemorrhage. N Engl J Med. 2016;375:1033 43. S9.4.1-3. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics 2017 update: a report from the American Heart Association. Circulation. 2017;135:e146 603. S9.4.1-4. ZhangY, Reilly KH, Tong W, et al. Blood pressure and clinical out- come among patients with acute stroke in Inner Mongolia. China J Hypertens. 2008;26:1446 52. S9.4.1-5. Rodriguez-Luna D, Pineiro S, Rubiera M, et al. Impact of blood pressure changes and course on hematoma growth in acute intrace- rebral hemorrhage. Eur J Neurol. 2013;20:1277 83. S9.4.1-6. Sakamoto Y, Koga M, Yamagami H, et al. Systolic blood pressure after intravenous antihypertensive treatment and clinical outcomes in hyperacute intracerebral hemorrhage: the Stroke Acute Management With Urgent Risk-Factor Assessment and Improvement-Intracerebral Hemorrhage Study. Stroke. 2013;44:1846 51. S9.4.1-7. Tsivgoulis G, Katsanos AH, Butcher KS, et al. Intensive blood pressure reduction in acute intracerebral hemorrhage: a meta-anal- ysis. Neurology. 2014;83:1523 9. S9.4.1-8. Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) investigators. Antihypertensive treatment of acute cere- bral hemorrhage. Crit Care Med. 2010;38:637 48. S9.4.1-9. Anderson CS, Huang Y, Wang JG, et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a ran- domised pilot trial. Lancet Neurol. 2008;7:391 9. 9.4.2. Acute Ischemic Stroke S9.4.2-1. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute isch- emic stroke. N Engl J Med. 1995;333:1581 7. S9.4.2-2. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317 29. S9.4.2-3. Ahmed N, Wahlgren N, Brainin M, et al. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR). Stroke. 2009;40:2442 9. S9.4.2-4. Robinson TG, Potter JF, Ford GA, et al. Effects of antihyperten- sive treatment after acute stroke in the Continue or Stop Post-Stroke AntihypertensivesCollaborativeStudy(COSSACS):aprospective,ran- domised, open, blinded-endpoint trial. Lancet Neurol. 2010;9:767 75. S9.4.2-5. He J, ZhangY, Xu T, et al. Effects of immediate blood pressure reduc- tion on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA. 2014;311:479 89. S9.4.2-6. Wang H, Tang Y, Rong X, et al. Effects of early blood pressure lowering on early and long-term outcomes after acute stroke: an updated meta-analysis. PLoS ONE. 2014;9:e97917. S9.4.2-7. Zhao R, Liu F-D, Wang S, et al. Blood pressure reduction in the acute phase of an ischemic stroke does not improve short- or long- term dependency or mortality: a meta-analysis of current literature. Medicine (Baltimore). 2015;94:e896. S9.4.2-8. Bath PM, Krishnan K. Interventions for deliberately altering blood pressure in acute stroke. Cochrane Database Syst Rev. 2014;10:CD000039. S9.4.2-9. Sandset EC, Bath PMW, Boysen G, et al. The angiotensin-recep- tor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet. 2011;377:741 50. S9.4.2-10. Qureshi AI, Ezzeddine MA, Nasar A, et al. Prevalence of elevated blood pressure in 563 704 adult patients with stroke presenting to the ED in the United States. Am J Emerg Med. 2007;25:32 8. S9.4.2-11. Leonardi-Bee J, Bath PM, Phillips SJ, et al. Blood pressure and clinical outcomes in the International Stroke Trial. Stroke. 2002;33:1315 20. S9.4.2-12. Castillo J, Leira R, Garcia MM, et al. Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome. Stroke. 2004;35:520 6. S9.4.2-13. Vemmos KN, Tsivgoulis G, Spengos K, et al. U-shaped relation- ship between mortality and admission blood pressure in patients with acute stroke. J Intern Med. 2004;255:257 65. S9.4.2-14. Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke. 2013;44:870 947. 9.4.3. Secondary Stroke Prevention S9.4.3-1. Liu L, Wang Z, Gong L, et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertens Res. 2009;32:1032 40. S9.4.3-2. Lakhan SE, Sapko MT. Blood pressure lowering treatment for pre- venting stroke recurrence: a systematic review and meta-analysis. Int Arch Med. 2009;2:30. S9.4.3-3. PROGRESS Collaborative Group. Randomised trial of a perin- dopril-based blood-pressure-lowering regimen among 6 105 indi- viduals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033 41. S9.4.3-4. PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J. 1995;108:710 7. S9.4.3-5. Lee M, Saver JL, Hong K-S, et al. Renin-angiotensin system modu- lators modestly reduce vascular risk in persons with prior stroke. Stroke. 2012;43:113 9. S9.4.3-6. Wang W-T, You L-K, Chiang C-E, et al. Comparative effectiveness of blood pressure-lowering drugs in patients who have already suf- fered from stroke: traditional and Bayesian network meta-analysis of randomized trials. Medicine (Baltimore). 2016;95:e3302. S9.4.3-7. Katsanos AH, Filippatou A, Manios E, et al. Blood pressure reduc- tion and secondary stroke prevention: a systematic review and metaregression analysis of randomized clinical trials. Hypertension. 2017;69:171 9. S9.4.3-8. Benavente OR, Coffey CS, Conwit R, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. SPS3 Study Group. Lancet. 2013;382:507 15. S9.4.3-9. Arima H, Chalmers J, Woodward M, et al. Lower target blood pres- sures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens. 2006;24:1201 8. S9.4.3-10. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics 2017 update: a report from the American Heart Association. Circulation. 2017;135:e146 603. S9.4.3-11. Dhamoon MS, Sciacca RR, Rundek T, et al. Recurrent stroke and cardiac risks after first ischemic stroke: the Northern Manhattan Study. Neurology. 2006;66:641 6. S9.4.3-12. Hardie K, Hankey GJ, Jamrozik K, et al. Ten-year risk of first recurrent stroke and disability after first-ever stroke in the Perth Community Stroke Study. Stroke. 2004;35:731 5. S9.4.3-13. Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology. 2004;62:569 73. S9.4.3-14. Toschke AM, Gulliford MC, Wolfe CDA, et al. Antihypertensive treatment after first stroke in primary care: results from the General Practitioner Research Database. J Hypertens. 2011;29:154 60. S9.4.3-15. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the preven- tion of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American StrokeAssociation. Stroke. 2014;45:2160 236. S9.4.3-16. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of car- diovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007;30:162 72. 9.5. Peripheral Artery Disease S9.5-1. Ostergren J, Sleight P, Dagenais G, et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J. 2004;25:17 24. S9.5-2. Thompson AM, Hu T, Eshelbrenner CL, et al. Antihypertensive treatment and secondary prevention of cardiovascular disease Whelton et al 2017 High Blood Pressure Clinical Practice Guideline e99 events among persons without hypertension: a meta-analysis. JAMA. 2011;305:913 22. S9.5-3. BavryAA,Anderson RD, GongY, et al. Outcomes among hyperten- sive patients with concomitant peripheral and coronary artery dis- ease: findings from the INternational VErapamil-SR/Trandolapril STudy. Hypertension. 2010;55:48 53. S9.5-4. Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens. 2006;24:2163 8. S9.5-5. Piller LB, Simpson LM, Baraniuk S, et al. Characteristics and long- term follow-up of participants with peripheral arterial disease dur- ing ALLHAT. J Gen Intern. Med. 2014;29:1475 83. 9.6. Diabetes Mellitus S9.6-1. Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313:603 15. S9.6-2. Arguedas JA, Leiva V, Wright JM. Blood pressure targets for hypertension in people with diabetes mellitus. Cochrane Database Syst Rev. 2013;10:CD008277. S9.6-3. Cushman WC, Evans GW, Byington RP, et al. Effects of inten- sive blood-pressure control in type 2 diabetes mellitus. ACCORD Study. N Engl J Med. 2010;362:1575 85. S9.6-4. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435 43. S9.6-5. Margolis KL, O'Connor PJ, Morgan TM, et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care. 2014;37:1721 8. S9.6-6. Soliman EZ, Byington RP, Bigger JT, et al. Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with diabetes mellitus: Action to Control Cardiovascular Risk in Diabetes Blood Pressure Trial. Hypertension. 2015;66:1123 9. S9.6-7. Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive blood pres- sure lowering on the progression of chronic kidney disease: a sys- tematic review and meta-analysis. CMAJ. 2013;185:949 57. S9.6-8. Bress AP, King JB, Kreider KE, et al. Effect of intensive versus standard blood pressure treatment according to baseline prediabe- tes status: a post hoc analysis of a randomized trial. Diabetes Care. 2017;40:1401 8. S9.6-9. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospec- tively designed overviews of randomized trials. Arch Intern Med. 2005;165:1410 9. S9.6-10. Whelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fast- ing glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165:1401 9. S9.6-11. Palmer SC, Mavridis D, Navarese E, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015;385:2047 56. S9.6-12. Schmieder RE, Hilgers KF, Schlaich MP, et al. Renin-angiotensin system and cardiovascular risk. Lancet. 2007;369:1208 19. S9.6-13. Reboussin DM, Allen NB, Griswold ME, et al. Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of theAmerican College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e116 e135. S9.6-14. Kannel WB, Wilson PW, Zhang TJ. The epidemiology of impaired glucose tolerance and hypertension. Am Heart J. 1991;121:1268 73. S9.6-15. Tarnow L, Rossing P, Gall MA, et al. Prevalence of arterial hyper- tension in diabetic patients before and after the JNC-V. Diabetes Care. 1994;17:1247 51. S9.6-16. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412 9. S9.6-17. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434 44. S9.6-18. Do DV, Wang X, Vedula SS, et al. Blood pressure control for dia- betic retinopathy. Cochrane Database Syst Rev. 2015;1:CD006127. S9.6-19. Estacio RO, Jeffers BW, Gifford N, et al. Effect of blood pressure con- trol on diabetic microvascular complications in patients with hyperten- sion and type 2 diabetes. Diabetes Care. 2000;23(suppl 2):B54 64. S9.6-20. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645 52. S9.6-21. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703 13. S9.6-22. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hyperten- sion: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755 62. S9.6-23. Reboldi G, Gentile G, Angeli F, et al. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73 913 patients. J Hypertens. 2011;29:1253 69. S9.6-24. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957 67. S9.6-25. Brunstrom M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ. 2016;352:i717. S9.6-26. PerkovicV, RodgersA. Redefining blood-pressure targets SPRINT starts the marathon. N Engl J Med. 2015;373:2175 8. S9.6-27. Mancia G, Schumacher H, Redon J, et al. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation. 2011;124:1727 36. Wright JT Jr, Probstfield JL, Cushman WC, et al. ALLHAT find- ings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med. 2009;169:832 42. 9.7. Metabolic Syndrome S9.7-1. Lim S, Eckel RH. Pharmacological treatment and therapeutic perspectives of metabolic syndrome. Rev Endocr Metab Disord. 2014;15:329 41. S9.7-2. Owen JG, Reisin E. Anti-hypertensive drug treatment of patients with and the metabolic syndrome and obesity: a review of evi- dence, meta-analysis, post hoc and guidelines publications. Curr Hypertens Rep. 2015;17:558. S9.7-3. Ruderman NB, Shulman GI. Metabolic syndrome. Jameson JL. Endocrinology: Adult & Pediatric. 2015; Elsevier Saunders: Philadelphia, PA:752 9. S9.7-4. Mozumdar A, Liguori G. Persistent increase of prevalence of meta- bolic syndrome among U.S. adults: NHANES III to NHANES 1999 2006. Diabetes Care. 2011;34:216 9. S9.7-5. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167 74. S9.7-6. Chen J, Gu D, Chen C-S, et al. Association between the metabolic syndrome and chronic kidney disease in Chinese adults. Nephrol Dial Transplant. 2007;22:1100 6. S9.7-7. Barzilay JI, Davis BR, Whelton PK. The glycemic effects of anti- hypertensive medications. Curr Hypertens Rep. 2014;16:410. S9.7-8. Kostis JB, Wilson AC, Freudenberger RS, et al. 